NL
DE
Radboudumc spin-off Aiosyn, a medical software company specializing in AI-powered pathology, has successfully closed a €2.4 million funding round. Participating investors are TNO Ventures, Oost NL, LUMO Labs, and Health Innovations. Alongside the funding, Aiosyn also announced a new strategic partnership with TNO, the Netherlands’ largest research and technology organization. The new funding and partnership will enable Aiosyn to accelerate the development and rollout of its AI-driven diagnostic solutions, aimed at improving cancer care through more efficient and precise pathology workflows.
Read the full release at Aiosyn’s website
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
go to page
Aiosyn selected as finalist for OostNL's Startversneller vote now!
18 October 2022The 6 finalists of the election “Starter with impact Eastern Netherlands 2022” have been announced and Radboudumc’s Aiosyn is one of them.
go to page.aspx?width=800&height=534&ext=.jpg&type=BlockColumn1Zoom1)
Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm
4 April 2022 Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides. go to page
